Navigation Links
Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Date:3/16/2009

1, 2008, compared with $5.9 million for the same period in 2007.

Beginning October 21, 2008, Pfizer became responsible for 60 percent of all Dimebon-related development and commercialization costs in the U.S., and 100 percent of such costs outside the U.S. The parties will make quarterly true-up payments as necessary to ensure that each bears its applicable share of costs. For the fourth quarter of 2008, the true-up payment payable to Medivation was $3.5 million. Medivation presents these cost-sharing true-up payments in the applicable expense line of its statement of operations.

Medivation reported a net loss for the quarter ended December 31, 2008, of $7.9 million, or $0.26 per share, compared with a net loss of $9.6 million, or $0.34 per share, for the same period in 2007. For the twelve months ended December 31, 2008, the net loss was $62.5 million, or $2.12 per share, compared with a net loss of $31.7 million, or $1.14 per share, for the same period in 2007.

Cash, cash equivalents and short-term investments at December 31, 2008, totaled $221.4 million, compared with $43.3 million at December 31, 2007.

2009 Financial Outlook

We expect 2009 revenue from our collaboration with Pfizer to be approximately $65 million, representing partial recognition of our $225 million up-front payment received. We do not expect to recognize any Dimebon related milestone payments in 2009. We expect that total operating expenses for 2009, net of cost-sharing payments from Pfizer, will be between $130 and $140 million, which includes non-cash stock-based compensation expense of approximately $10 million.

Conference Call Information

To participate in today's live call beginning at 4:30 p.m. Eastern Time by telephone, please call 877-718-5104 from the U.S. or +1-719-325-4794 internationally. In addition, the live conference call is being webcast and can be access
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
2. Medivation Presents New Data on Dimebons Novel Mechanism of Action
3. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
4. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
5. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
6. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
7. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
9. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
10. Medivation Announces Participation in Upcoming Conferences
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
(Date:10/20/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... $5.8 million and provides a good start to Q4.  The orders ... and one in the Middle East ... levels," said Peter Bruijns , President & CEO. "Total bidding ... than they have been for any complete year since the company ...
(Date:10/20/2014)... Earle Martin , Chief Executive ... Ellen Teplitzky, an experienced attorney specializing in business ... has joined the firm as Director of Legal ... NDA Partners provides legal services, including research, ... top law firms and their clients in cases ...
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines and ... and forecast of revenue. , Browse through the ... to get an idea of the in-depth analysis ... segmentation in the Asia-Pacific bromine market, and is ... http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a volatile ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... the ENCODE, or Encyclopedia Of DNA Elements project, has created ... human genome sequence. The April 19 publication ... (ENCODE)" in the journal PLoS Biology provides a guide for ... so far by the project. All of the data, ...
... SEGUNDO, Calif., April 21, 2011 A longtime engineer ... Space Technology Hall of Fame for his participation in ... cancer tumors and virus cultures outside the body, both ... Trinh, a senior mechanical engineer and 26-year employee at ...
... questions over a billion dollar industry by boldly claiming ... materials can be mass produced. In a ... journal Nanotechnology , Professor Mike Kelly, Centre for ... you cannot mass produce structures with a diameter of ...
Cached Biology Technology:A user's guide to the encyclopedia of DNA elements 2Wyle Engineer Inducted Into Space Technology Hall of Fame for Work on Growing Human Cells in Space 2Limit to nanotechnology mass-production? 2
(Date:10/15/2014)... Gauß-Allianz has admitted Johannes Gutenberg University Mainz (JGU) ... science hub continues to maintain a significant nationwide ... , "The acceptance of Johannes Gutenberg University Mainz ... a milestone in the national and international competition ... state of Rhineland-Palatinate can be proud that Mainz ...
(Date:10/15/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD and ... the growing mobile commerce market releases photos and video of the ... Monday October 13 th . Gino Pereira ... and angel investor Mr. Chad A. Verdi rang the ... thanked his investors and employees "for their work and dedication in ...
(Date:10/14/2014)... prostate cancer tumors scavenge and hoard copper that is ... may be a fatal weakness. , Researchers at ... cancer cells by delivering a trove of copper along ... brimming with the mineral, leaving non-cancer cells healthy. , ... available for other uses, could soon be tested in ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2
... yourself with a blanket to stave off the shivers? ... help alleviate shivering in patients who have been cooled ... or dangerously high fevers are often cooled to reduce ... aid healing. Unfortunately, cooling induces a natural and familiar ...
... Tiny flying machines can be used for everything ... simply making smaller versions of planes and helicopters ... Carolina State University are mimicking nature,s small flyers ... maneuverability and performance. Small flyers, or micro-aerial ...
... from the British Antarctic Survey have collected individuals from a ... subjected them to increasing levels of water temperature to learn ... that they are likely to experience in the future. The ... really close to their upper temperature range, and that further ...
Cached Biology News:Robo-bats with metal muscles may be next generation of remote control flyers 2
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
KOR-1 (C-20)...
...
Biology Products: